Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 718-722

  Walther, McClellan M ^b   Johnson, Bruce ^b   Culley, Donald ^b   Shah, Reena ^b   Weber, Jeff ^a   Venzon, David ^b   Yang, James C ^b   Linehan, W Marston ^b   Rosenberg, Steven A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

Carcinoma; Interleukin 2; Interleukin 6; Kidney; Neoplasm metastasis; Renal cell

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; GENE FREQUENCY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 0031931085     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63709-1     Document Type: Article

References (33)

1. May, L. T., Helfgott, D. C. and Sehgal, P. B.: Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved. Proc. Natl. Acad. Sci., 83: 8957, 1986.
2. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K. and Iwamatsu, A.: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 324: 73, 1986.
3. Houssiau, F. A., Coulie, P. G., Olive, D. and Van Snick, J.: Synergistic activation of human T cells by interleukin 1 and interleukin 6. Eur. J. Immunol., 18: 653, 1988.
4. Fukatsu, A., Matsuo, S., Tamai, H., Sakamoto, N., Matsuda, T. and Hirano, T.: Distribution of interleukin-6 in normal and diseased human kidney. Lab. Invest., 65: 61, 1991.
5. Boswell, R. N., Yard, B. A., Schrama, E., van Es, L. A., Daha, M. R. and van der Woude, F. J.: Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol. Dial. Transplant., 9: 599, 1994.
6. Takenawa, J., Kaneko, Y., Fukumoto, M., Fukatsu, A., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J. and Yoshida, O.: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Nat. Cancer Inst., 83: 1668, 1991.
7. Koo, A. S., Armstrong, C., Bochner, B., Shimabukuro, T., Tso, C. L., deKernion, J. B. and Belldegrum, A.: Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol. Immunother., 35: 97, 1992.
8. Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D. and Rosenberg, S. A.: A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emph. Tumor Immunol., 15: 292, 1994.
9. Nieken, J., Mulder, N. H., Buter, J., Vellenga, E., Limburg, P. C., Piers, D. A. and de Vries, E. G.: Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood, 86: 900, 1995.
10. Fujimoto, N., Sugita, A., Terasawa, Y. and Kato, M.: Observations on the growth rate of renal cell carcinoma. Int. J. Urol., 2: 71, 1995.
11. Stauffer, M. H.: Nephrogenic hepatosplenomegaly. Gastroenterology, 40: 694, 1961.
12. Boxer, R. J., Waisman, J., Lieber, M. M., Mampaso, F. M. and Skinner, D. G.: Non-metastatic hepatic dysfunction associated with renal carcinoma. J. Urol., 119: 468, 1978.
13. Blay, J. Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M. and Moskovtchenko, J. F.: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317, 1992.
14. Tartour, E., Blay, J. Y., Dorval, T., Escudier, B., Mosseri, V., Douillard, J. Y., Deneux, L., Gorin, I., Negrier, S. and Mathiot, C.: Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J. Clin. Oncol., 14: 1697, 1996.
15. Lissoni, P., Barni, S., Ardizzoia, A., Scardino, E., Tancini, G. and Vigano, M. G.: Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients. J. Biol. Reg. Homeost. Agents, 9: 21, 1995.
16. Shih, Y., Konrad, M. W., Warren, M. K., Childs, A., Paradise, C., Meyers, F. J. and Groves, E. S.: Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. Eur. J. Immunol., 22: 727, 1992.
17. Meffert, M., Hanninen, E. L., Menzel, T., Schomburg, A., Duensing, S., Dallmann, I., Grosse, J., Vocke, S., Buer, J. and Deckert, M.: In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2. Cancer Biother., 9: 307, 1994.
18. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J.A.M.A., 271: 907, 1994.
19. Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Parkinson, D. R., Marincola, F. M., Weber, J. S., Seipp, C. A., White, D. E. and Rosenberg, S. A.: The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer, 76: 687, 1995.
20. Marincola, F. M., White, D. E., Wise, A. P. and Rosenberg, S. A.: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol., 13: 1110, 1995.
21. Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J. and Kim, H. I.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol., 12: 1572, 1994.
22. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M. and Seipp, C. A.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Nat. Cancer Inst., 85: 622, 1993.
23. Lange, J. R., Raubitschek, A. A., Pockaj, B. A., Spencer, W. F., Lotze, M. T., Topalian, S. L., Yang, J. C. and Rosenberg, S. A.: A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J. Immunother., 12: 265, 1992.
24. Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. L., Linehan, W. M., Lotze, M. T., Robertson, C. N., Seipp, C. A. and Simon, P.: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol., 6: 839, 1988.
25. Walther, M. M., Patel, B., Choyke, P. L., Lubensky, I. A., Vocke, C. D., Harris, C., Venzon, D., Burtis, W. J. and Linehan, W. M.: Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J. Urol., 158: 733, 1997.
26. Van Oers, M. H., Van der Heyden, A. A. and Aarden, L. A.: Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin. Exp. Immunol., 71: 314, 1988.
27. Hayat, K., Rodgers, S., Bruce, L., Rees, R. C., Chapman, K., Reeder, S., Dorreen, M. S., Sheridan, E., Sreenivasan, T. and Hancock, B. W.: Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2. Eur. J. Cancer, 27: 1009, 1991.
28. Tsukamoto, T., Kumamoto, Y., Miyao, N., Masumori, N., Takahashi, A. and Yanase, M.: Interleukin-6 in renal cell carcinoma. J. Urol., 148: 1778, 1992.
29. Stouthard, J. M., Goey, H., de Vries, E. G., de Mulder, P. H., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H. P., Bakker, P. J. and Veenhof, C. H.: Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Brit. J. Cancer, 73: 789, 1996.
30. Nijsten, M. W., de Groot, E. R., ten Duis, H. J., Klasen, H. J., Hack, C. E. and Aarden, L. A.: Serum levels of interleukin-6 and acute phase responses. Lancet, 2: 921, 1987.
31. Utz, D. C., Warren, M. M., Gregg, J. A., Ludwig, J. and Kelalis, P. P.: Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin. Proc., 45: 161, 1970.
32. Walsh, P. N. and Kissane, J. M.: Nonmetastatic hypernephroma with reversible hepatic dysfunction. Arch. Intern. Med., 122: 214, 1968.
33. Andrassy, K., Gartner, H., Siede, W. H., Ritz, E., Riedasch, G., Mohring, K., Zimmermann, R. and Matouschek, E.: Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation. Klin. Wochenschr., 58: 91, 1980.